Having sped read that report, whilst the valuation sticks out like a sore thumb from where we are now they do state they need over $200m in capital to get there. However, Mercks take over of Cubist (Daptomysin) in 2014 for $9.5billion tells you where this could go.
Given sepsis appears to be THE largest cost to the US medical system (and no doubt many others) I have a strong suspicion that anyone with some nouse at a big pharma, simply cannot let this product get into competitors hands because the $'s involved could be immense.
So, in short, I think we see positive results from trials and then a big pharma come of board with a licensing type deal, which funds the trials going forward and lets RCE shareholders have upside exposure, though probably giving away half the farm. I can live with that because the Australian capital markets are so short sighted when it comes to biotech they will not get their heads around this to allow it to be funded from Australia and succeed as an Australian entity.
Having sped read that report, whilst the valuation sticks out...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.0¢ | $21.54K | 57.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3248 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49884 | 1 |
View Market Depth
| Last trade - 14.27pm 30/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |